CTXRW
Income statement / Annual
Last year (2024), Citius Pharmaceuticals Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Citius Pharmaceuticals Inc's net income was -$39.43 M.
See Citius Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2013
|
| Period Ended |
09/30/2024 |
12/31/2023 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
09/30/2015 |
09/30/2013 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$75.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$75.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$90.00 K
|
$0.00
|
$0.00
|
$806.00
|
$3.07 K
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$11.91 M
|
$11.91 M
|
$12.24 M
|
$8.81 M
|
$8.60 M
|
$6.56 M
|
$2.93 M
|
$2.93 M
|
$1.80 M
|
$0.00
|
| General & Administrative Expenses |
$18.25 M
|
$18.25 M
|
$9.84 M
|
$8.10 M
|
$6.29 M
|
$6.45 M
|
$3.78 M
|
$3.78 M
|
$946.61 K
|
$2.89 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$18.25 M
|
$18.25 M
|
$9.84 M
|
$8.10 M
|
$6.29 M
|
$6.45 M
|
$3.78 M
|
$3.78 M
|
$946.61 K
|
$2.89 K
|
| Other Expenses |
$11.84 M
|
$11.84 M
|
$1.46 M
|
$803.26 K
|
$715.98 K
|
$779.70 K
|
$732.15 K
|
$732.15 K
|
$486.27 K
|
$25.23 K
|
| Operating Expenses |
$42.00 M
|
$42.00 M
|
$23.53 M
|
$17.71 M
|
$15.60 M
|
$13.79 M
|
$7.45 M
|
$7.45 M
|
$3.23 M
|
$28.12 K
|
| Cost And Expenses |
$0.00
|
$0.00
|
$23.53 M
|
$17.71 M
|
$15.60 M
|
$13.86 M
|
$7.45 M
|
$7.45 M
|
$3.23 M
|
$28.12 K
|
| Interest Income |
$0.00
|
$0.00
|
$261.83 K
|
$68.07 K
|
$52.66 K
|
$0.00
|
$806.00
|
$806.00
|
$3.07 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$10.84 K
|
$15.67 K
|
$16.44 K
|
$15.84 K
|
$8.99 K
|
$8.99 K
|
$7.50 K
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
$164.87 K
|
$152.36 K
|
$893.00
|
$1.75 K
|
$1.34 K
|
$1.34 K
|
$335.16 K
|
-$3.25 K
|
| EBITDA |
$0.00 |
$0.00 |
-$22.88 M |
-$17.38 M |
$15.58 M |
-$12.52 M |
-$8.29 M |
-$8.29 M |
-$2.90 M |
$0.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
-166.92
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
-183.85
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$0.00
|
$0.00
|
$477.46 K
|
$162.60 K
|
$31.16 M
|
$1.25 M
|
$1.69 M
|
-$846.00 K
|
$327.66 K
|
-$3.25 K
|
| Income Before Tax |
-$38.85 M
|
-$38.85 M
|
-$23.05 M
|
-$17.55 M
|
$15.56 M
|
-$12.54 M
|
-$8.30 M
|
-$8.30 M
|
-$2.90 M
|
-$31.37 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
-167.16
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$576.00 K
|
$576.00 K
|
$0.00
|
$0.00
|
$31.18 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$39.43 M
|
-$39.43 M
|
-$23.05 M
|
-$17.55 M
|
-$15.56 M
|
-$12.54 M
|
-$8.30 M
|
-$8.30 M
|
-$2.90 M
|
-$31.37 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
-167.16
|
0
|
0
|
0
|
0
|
| EPS |
-5.86 |
-5.97 |
-0.66 |
-0.5 |
-0.77 |
-1.17 |
-0.57 |
-0.41 |
-0.15 |
-0.0017 |
| EPS Diluted |
-5.86 |
-5.97 |
-0.66 |
-0.5 |
-0.77 |
-1.17 |
-0.57 |
-0.41 |
-0.15 |
-0.0017 |
| Weighted Average Shares Out |
$6.73 M
|
$6.73 M
|
$35.02 M
|
$35.02 M
|
$20.16 M
|
$10.73 M
|
$14.52 M
|
$20.43 M
|
$19.22 M
|
$18.00 M
|
| Weighted Average Shares Out Diluted |
$6.73 M
|
$6.73 M
|
$35.02 M
|
$35.02 M
|
$20.16 M
|
$10.73 M
|
$14.52 M
|
$20.43 M
|
$19.22 M
|
$18.00 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
